Minerva Neurosciences Q2 2025 Earnings Report

Minerva Neurosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.95
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Minerva Neurosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Minerva Neurosciences Announcement Details

• Quarter: Q2 2025
• Date: 8/5/2025
• Time: Before Market Opens
• Conference Call Date: Friday, August 1, 2025
• Conference Call Time: 9:30AM ET

Minerva Neurosciences (NASDAQ:NERV). (NASDAQ: NERV) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for central nervous system (CNS) disorders. Founded in 2004 and headquartered in Boston, Massachusetts, Minerva’s research platform leverages insights into neurotransmitter systems to identify novel small molecules and biologics aimed at unmet medical needs in psychiatry and neurology.

The company’s lead candidate, seltorexant (MIN-202), is a selective orexin-2 receptor antagonist being evaluated for the treatment of major depressive disorder and associated sleep disturbances. In parallel, Minerva is advancing MIN-117, a multimodal serotoninergic and adrenergic agent designed to address depression in patients who have shown inadequate response to existing therapies. Preclinical programs targeting cognitive impairment and neurodegenerative indications further diversify the company’s pipeline.

Minerva Neurosciences operates across North America and Europe, conducting its clinical trials in diverse patient populations to ensure broad applicability of its results. The company maintains strategic collaborations with contract research organizations and academic centers to support its Phase 1–3 studies. Manufacturing partnerships in the United States and Europe enable scalable production of investigational compounds.

Under the leadership of President and Chief Executive Officer Umer Raffat, Minerva has built a management team with deep expertise in CNS drug development, regulatory affairs and commercial strategy. Since its initial public offering in 2015, the company has pursued a disciplined approach to advancing its pipeline, aiming to bring first-in-class therapies to patients with limited treatment options in the psychiatric and neurological space.